表紙
市場調査レポート

世界の分子診断市場の見通し

Global Molecular Diagnostics Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 346848
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
世界の分子診断市場の見通し Global Molecular Diagnostics Market Outlook 2020
出版日: 2015年12月07日 ページ情報: 英文 60 Pages
概要

世界の分子診断市場は、2015年〜2020年のCAGRで、10.8%の成長が予測されています。

当レポートでは、世界の分子診断市場について調査分析し、市場の現状と見通し、主要動向、促進要因と抑制要因、競合情勢など、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 分子診断:イントロダクション

第4章 市場力学

  • 促進要因
  • 抑制要因
  • 動向
  • 機会

第5章 分子診断市場の概要

  • 現在の市場規模と将来成長

第6章 分子診断市場:応用別

  • イントロダクション
    • 感染症
    • 腫瘍
    • 血液検査
    • 遺伝子検査

第7章 分子診断市場:技術別

  • イントロダクション
    • PCR
    • 核酸ハイブリッド形成
    • DNAシークエンシングとNGS

第8章 分子診断市場:地域別

  • イントロダクション
    • 北米
    • 欧州
    • アジア太平洋地域

第9章 主要企業分析

  • Abbott Diagnostics
  • Alere Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cepheid
  • Danaher Corporation
  • Roche Diagnostics
  • Hologic, Inc.
  • QIAGEN N.V.
  • Siemens Healthcare
  • Thermo Fisher Scientific Inc.

図表

目次

Molecular diagnostics has revolutionized the healthcare industry by providing more rapid, sensitive and specific diagnostic tests in contrast to the traditional techniques. Since its inception, the molecular diagnostics has witnessed various technological advancements which have made this technique more efficient and effective. With growing awareness and adoption of this sophisticated technique, the molecular diagnostic market is expected to surge in the future.

According to a new analysis from RNCOS in “Global Molecular Diagnostics Market Outlook 2020” report, the Global Molecular Diagnostics Market is anticipated to grow at a healthy CAGR of 10.8% during the forecast period (2015 to 2020). The market growth is expected mainly due to the growing incidences of cancer and infectious diseases, and increasing awareness about personalized medicine and biomarkers. Furthermore, the improving reimbursement scenario and strategic alliances among major players are other factors driving the growth of the market. There are also various opportunities present for the new incumbents into the market which include overall growth of interest in genetic testing and rise of emerging markets. The report provides information on the current scenario, market outlook on the basis of application, technology and geography, and future forecasts on all prominent segments of the industry till 2020.

According to the analysis by RNCOS, the infectious diseases segment dominates the molecular diagnostics market by application; however it is the oncology segment which is expected to witness the maximum growth in the coming years. This high growth is likely to be driven by the increasing incidences of cancer and growing awareness of the new sophisticated tests available for early cancer detection. Similarly, PCR dominates the molecular diagnostics market by technology and the DNA Sequencing and Next Generation Sequencing (NGS) segment is expected to witness the maximum growth. This growth could be attributed to the availability of cost effective sequencing methods. In terms of geography, North America continues to dominate the market, but it is the Asia Pacific market, which is expected to witness the highest growth, largely due to improving medical facilities and increasing focus of various players in this region.

The later part of the report focuses on existing competition in the industry. Major players operating in this market include Roche Diagnostics, Abbott Diagnostics, Becton Dickinson, and Hologic, among others. The competitive analysis is done at each player level, including their recent developments and a SWOT analysis. To provide a thorough understanding of each player's business model, the player's current and historical financials have been analyzed. On the whole, the study included in the report provides a detailed market overview, current and future scenario, and industry trends which will likely generate key interest in investors thinking about joining the industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Molecular Diagnostics - An Introduction

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Incidence of Cancer and Infectious Diseases
    • 4.1.2. Benefits of Molecular Diagnostic Tests Over Traditional Methods
    • 4.1.3. Increasing Awareness of Personalized Medicine, Biomarkers,& Companion Diagnostics
    • 4.1.4. Technological Advancements
    • 4.1.5. Improving Reimbursement Scenario
  • 4.2. Restraints
    • 4.2.1. High Costs of Molecular Diagnostics Tests
    • 4.2.2. Regulatory Issues Related to Molecular Diagnostics Tests
  • 4.3. Trends
    • 4.3.1. Upsurge in the Number of Strategic Alliances
    • 4.3.2. Automation & Multiplexing: A Growing Trend
  • 4.4. Opportunities
    • 4.4.1. Significant Growth Opportunities in Emerging Markets
    • 4.4.2. Genetic Testing: A New Revenue Pocket for Molecular Diagnostics Market

5. Molecular Diagnostics Market Overview

  • 5.1. Current Market Size and Future Growth

6. Molecular Diagnostics Market, By Application

  • 6.1. Introduction
    • 6.1.1. Infectious Diseases
    • 6.1.2. Oncology
    • 6.1.3. Blood Screening
    • 6.1.4. Genetic Testing

7. Molecular Diagnostics Market, By Technology

  • 7.1. Introduction
    • 7.1.1. Polymerase Chain Reaction (PCR)
    • 7.1.2. Nucleic Acid Hybridization
    • 7.1.3. DNA Sequencing and Next Generation Sequencing (NGS)

8. Molecular Diagnostic Market, By Region

  • 8.1. Introduction
    • 8.1.1. North America
    • 8.1.2. Europe
    • 8.1.3. Asia Pacific

9. Key Player Analysis

  • 9.1. Abbott Diagnostics (A Division of Abbott Laboratories)
  • 9.2. Alere Inc.
  • 9.3. Becton, Dickinson and Company
  • 9.4. bioMérieux SA
  • 9.5. Cepheid
  • 9.6. Danaher Corporation
  • 9.7. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG) 52
  • 9.8. Hologic, Inc.
  • 9.9. QIAGEN N.V.
  • 9.10. Siemens Healthcare
  • 9.11. Thermo Fisher Scientific Inc.

List of Figures:

  • Figure 5-1: Global - Molecular Diagnostics Market (Billion US$), 2015-2020
  • Figure 6-1: Global - Molecular Diagnostics Market by Application (%), 2015
  • Figure 6-2: Global - Molecular Diagnostics Market by Application (%), 2020
  • Figure 6-3: Global - Infectious Disease Market (Billion US$), 2015-2020
  • Figure 6-4: Global - Oncology Market (Billion US$), 2015-2020
  • Figure 6-5: Global - Blood Screening Market (Billion US$), 2015-2020
  • Figure 6-6: Global - Genetic Testing Market (Billion US$), 2015-2020
  • Figure 7-1: Global - Molecular Diagnostics Market by Technology (%), 2015
  • Figure 7-2: Global - Molecular Diagnostics Market by Technology (%), 2020
  • Figure 7-3: Global - PCR Market (Billion US$), 2015-2020
  • Figure 7-4: Global - Nucleic Acid Hybridization Market (Billion US$), 2015-2020
  • Figure 7-5: Global - DNA Sequencing and NGS Market (Billion US$), 2015-2020
  • Figure 8-1: Global - Molecular Diagnostics Market by Region (%), 2015
  • Figure 8-2: Global - Molecular Diagnostics Market by Region (%), 2020
  • Figure 8-3: North America - Molecular Diagnostics Market (Billion US$), 2015-2020
  • Figure 8-4: North America - Molecular Diagnostics Market by Country (%), 2015
  • Figure 8-5: Europe - Molecular Diagnostics Market (Billion US$), 2015-2020
  • Figure 8-6: Europe - Molecular Diagnostics Market by Country (%), 2015
  • Figure 8-7: Asia Pacific - Molecular Diagnostics Market (Billion US$), 2015-2020
  • Figure 8-8: Asia Pacific - Molecular Diagnostics Market by Country (%), 2015
  • Figure 9-1: Abbott Laboratories - Break up of Revenue by Reportable Business Segment (%), 2014
  • Figure 9-2: Alere Inc. - Break up of Revenue by Reportable Business Segment (%), 2014
  • Figure 9-3: Alere Inc. - Professional Diagnostic Division Revenue by Segment (%), 2014
  • Figure 9-4: Becton, Dickinson and Company - Break up of Revenue by Business Segment (%), 2014
  • Figure 9-5: Becton, Dickinson and Company - Diagnostic Division Revenue by Segment (%), 2014
  • Figure 9-6: bioMérieux SA - Break up of Revenue by Applications (%), 2014
  • Figure 9-7: bioMérieux SA - Clinical Application Revenue by Segment (%), 2014
  • Figure 9-8: Cepheid - Break up of Revenue by Business Segment (%), 2014
  • Figure 9-9: Danaher Corporation - Break up of Revenue by Business Segment (%), 2014
  • Figure 9-10: Roche AG - Break up of Revenue by Business Segment (%), 2014
  • Figure 9-11: Roche AG - Diagnostic Division Revenue by Segment (%), 2014
  • Figure 9-12: Hologic, Inc. - Break up of Revenue by Business Segment (%), 2015
  • Figure 9-13: Hologic, Inc. - Diagnostic Division Revenue by Segment (%), 2015
  • Figure 9-14: QIAGEN N.V. - Break up of Revenue by Business Segment (%), 2014
  • Figure 9-15: Thermo Fisher Scientific Inc. - Break up of Revenue by Business Segment (%), 2014

List of Tables:

  • Table 6-1: Global - Molecular Diagnostic Market by Application (Billion US$), 2015
  • Table 6-2: Global - Molecular Diagnostic Market by Application (Billion US$), 2020
  • Table 7-1: Global - Molecular Diagnostic Market by Technology (Billion US$), 2015
  • Table 7-2: Global - Molecular Diagnostic Market by Technology (Billion US$), 2020
  • Table 8-1: Global - Molecular Diagnostic Market by Region (Billion US$), 2015
  • Table 8-2: Global - Molecular Diagnostic Market by Region (Billion US$), 2020
  • Table 9-1: Abbott Laboratories - Key Financials (Million US$), 2012-2014
  • Table 9-2: Abbott Diagnostics - Product Portfolio for Molecular Diagnostics
  • Table 9-3: Alere Inc. - Key Financials (Million US$), 2012-2014
  • Table 9-4: Alere Inc. - Product Portfolio for Molecular Diagnostics
  • Table 9-5: Becton, Dickinson and Company - Key Financials (Million US$), 2012-2014
  • Table 9-6: Becton, Dickinson and Company - Product Portfolio for Molecular Diagnostics
  • Table 9-7: bioMérieux SA - Key Financials (Million US$) 2012-2014
  • Table 9-8: bioMérieux SA - Product Portfolio for Molecular Diagnostics
  • Table 9-9: Cepheid - Key Financials (Million US$), 2012-2014
  • Table 9-10: Cepheid - Product Portfolio for Molecular Diagnostics
  • Table 9-11: Danaher Corporation - Key Financials (Million US$) 2012-2014
  • Table 9-12: Danaher Corporation - Product Portfolio for Molecular Diagnostics
  • Table 9-13: Roche AG - Key Financials (Million US$), 2012-2014
  • Table 9-14: Roche AG - Product Portfolio for Molecular Diagnostics
  • Table 9-15: Hologic, Inc. - Key Financials (Million US$) 2013-2015
  • Table 9-16: Hologic, Inc. - Product Portfolio for Molecular Diagnostics
  • Table 9-17: QIAGEN N.V. - Key Financials (Million US$), 2012-2014
  • Table 9-18: QIAGEN N.V. - Product Portfolio for Molecular Diagnostics
  • Table 9-19: Siemens Healthcare - Key Financials (Million US$), 2012-2014
  • Table 9-20: Siemens Healthcare - Product Portfolio for Molecular Diagnostics
  • Table 9-21: Thermo Fisher Scientific Inc. - Key Financials (Million US$) 2012-2014
  • Table 9-22: Thermo Fisher Scientific Inc. - Product Portfolio for Molecular Diagnostics
Back to Top